Stockreport

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Immunome, Inc.  (IMNM) 
PDF BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therap [Read more]